US Patent 8592156 Predicting response to anti-CD20 therapy in DLBCL patients
Patent 8592156 was granted and assigned to Roche Molecular Systems on November, 2013 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 8592156 Predicting response to anti-CD20 therapy in DLBCL patients
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.